Jean-François Formela

Jean-François Formela is a partner in the life sciences group and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics.

He serves on the boards of Annovation Biopharma, Ataxion, F-star, Intellia Therapeutics, Navitor, and RaNA Therapeutics, which he co-founded. He is the chairman of Egalet (NASDAQ: EGLT) and Spero Therapeutics.

Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Arteaus Therapeutics (acquired by Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM), and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Lilly).  He was also an investor in Achillion (NASDAQ: ACHN), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).

Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise.  Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas.  Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon.  Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.

Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a trustee of the Boston Institute of Contemporary Art.

He received his MD from Paris University School of Medicine, and his MBA from Columbia University.